Promising outcomes with surufatinib-vinorelbine combination therapy in lung cancer with neuroendocrine differentiation

#4104

Introduction: Lung cancer (LC) remains one of the most prevalent and deadly cancers worldwide. Neuroendocrine differentiation (NED) is observed in 25-33% of LC cases. NSCLC patients with NED (NSCLC-NED) often have worse outcomes, resembling SCLC behaviour.

Aim(s): Effective treatments are lacking, highlighting the need for research. The study aims to investigate the efficacy and safety of surufatinib combined with vinorelbine in the treatment of NSCLC-NED.

Materials and methods: Patients (Pts) with advanced LC, either progressing or intolerant after systemic therapy, were enrolled. Eligible Pts exhibited positive neuroendocrine markers (Syn, CgA, CD56) or NSE levels ≥15.2ng/ml, and were either negative for EGFR, ALK, ROS1 mutations or had developed resistance/intolerance to corresponding targeted therapies. Treatment involved up to six cycles of surufatinib and vinorelbine, followed by surufatinib maintenance. The study primarily assessed PFS, DCR and safety.

Conference:

Presenting Author:

Authors: Chai M, Zhang Y, Wang Y, Lu Z, Xie J,

Keywords: NSCLC-NED, treatment, surufatinib, vinorelbine,